AAM commends the Supreme Court for upholding the constitutionality of the Inter Partes Review (IPR) process. This is a win for patients who depend on continued access to safe, effective and affordable generic and biosimilar medicines. IPR helps enhance patient access to generic and biosimilar medicines by providing a more efficient mechanism for determining whether the patents of brand-name drug manufacturers are valid.
ATTRIBUTE TO: Jeff Francer, Senior Vice President & General Counsel
CONTACT:
Rachel Schwartz
202.249.7147 (o)
202.251.8881 (c)
